JP2023545662A5 - - Google Patents

Info

Publication number
JP2023545662A5
JP2023545662A5 JP2023519770A JP2023519770A JP2023545662A5 JP 2023545662 A5 JP2023545662 A5 JP 2023545662A5 JP 2023519770 A JP2023519770 A JP 2023519770A JP 2023519770 A JP2023519770 A JP 2023519770A JP 2023545662 A5 JP2023545662 A5 JP 2023545662A5
Authority
JP
Japan
Prior art keywords
lys
pharmaceutically acceptable
acceptable salt
aib
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023519770A
Other languages
English (en)
Japanese (ja)
Other versions
JP7830441B2 (ja
JP2023545662A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/059420 external-priority patent/WO2022079639A1/en
Publication of JP2023545662A publication Critical patent/JP2023545662A/ja
Publication of JP2023545662A5 publication Critical patent/JP2023545662A5/ja
Application granted granted Critical
Publication of JP7830441B2 publication Critical patent/JP7830441B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023519770A 2020-10-17 2021-10-13 Glp-1/gip二重アゴニスト Active JP7830441B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202021045240 2020-10-17
IN202021045240 2020-10-17
IN202121002837 2021-01-20
IN202121002837 2021-01-20
PCT/IB2021/059420 WO2022079639A1 (en) 2020-10-17 2021-10-13 Glp-1/gip dual agonists

Publications (3)

Publication Number Publication Date
JP2023545662A JP2023545662A (ja) 2023-10-31
JP2023545662A5 true JP2023545662A5 (https=) 2024-10-18
JP7830441B2 JP7830441B2 (ja) 2026-03-16

Family

ID=78302859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519770A Active JP7830441B2 (ja) 2020-10-17 2021-10-13 Glp-1/gip二重アゴニスト

Country Status (16)

Country Link
US (2) US20240020543A1 (https=)
EP (1) EP4204440A1 (https=)
JP (1) JP7830441B2 (https=)
KR (1) KR20230088337A (https=)
CN (1) CN116171164A (https=)
AU (1) AU2021361263A1 (https=)
BR (1) BR112023003668A2 (https=)
CA (1) CA3195155A1 (https=)
CL (1) CL2023000960A1 (https=)
CO (1) CO2023001960A2 (https=)
IL (1) IL301109A (https=)
JO (1) JOP20230077A1 (https=)
MX (1) MX2023002906A (https=)
PE (1) PE20231309A1 (https=)
TW (1) TW202229323A (https=)
WO (1) WO2022079639A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
US12281149B2 (en) 2021-05-13 2025-04-22 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
EP4556487A1 (en) * 2022-07-13 2025-05-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1/gip dual agonist, and preparation method therefor and use thereof
WO2024020388A1 (en) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
WO2024098718A1 (zh) * 2022-11-07 2024-05-16 内蒙古博睿精创科技有限公司 一种新型长效多肽化合物、组合物及其应用
CN115651075B (zh) * 2022-12-12 2023-04-11 杭州信海医药科技有限公司 一种Tirzepatide的合成方法
CN120865433A (zh) * 2022-12-21 2025-10-31 勃林格殷格翰国际有限公司 Glp1/gip/npy2受体的三重激动剂
JP2025530024A (ja) * 2023-01-18 2025-09-10 シャンハイ ミンウェイ バイオテクノロジー カンパニー,リミテッド 三重活性を有する融合タンパク質およびその応用
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
TW202500575A (zh) * 2023-05-21 2025-01-01 美商卡默療法股份有限公司 具有或不具有體重相關合併症之過重或肥胖成人之治療
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
WO2025163615A1 (en) 2024-01-31 2025-08-07 Sun Pharmaceutical Industries Ltd. High level production of glp1 analogues
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007224019A1 (en) 2006-03-03 2007-09-13 California Institute Of Technology Site-specific incorporation of amino acids into molecules
IN2014MN02304A (https=) 2012-05-03 2015-08-07 Zealand Pharma As
CN104583232B (zh) * 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
TWI582109B (zh) 2015-01-09 2017-05-11 美國禮來大藥廠 Gip及glp-1共促效劑化合物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
MX2020010505A (es) * 2018-04-05 2021-01-15 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1.
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
CN119499352A (zh) 2018-07-23 2025-02-25 伊莱利利公司 使用gip/glp1共激动剂用于糖尿病的方法
KR20240051304A (ko) 2018-07-23 2024-04-19 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型glp-1/gip雙重促效劑

Similar Documents

Publication Publication Date Title
JP2023545662A5 (https=)
JP2023530515A5 (https=)
JP7830441B2 (ja) Glp-1/gip二重アゴニスト
JP2024525732A (ja) インターロイキン-23受容体の脂質化ペプチド阻害剤
US7052695B2 (en) Angiopoietins and methods of treating hypertension
JP2009191078A5 (https=)
JP2004536077A5 (https=)
JP2005511503A5 (ja) 過剰体重を防止または治療するためのオキシントモジュリン
JP6685046B2 (ja) 長時間作用型アドレノメデュリン誘導体
CN102171244A (zh) 糖依赖性胰岛素释放肽的类似物
JP2003503312A5 (https=)
RU2007110981A (ru) Урокортин iii и его использование
KR102152437B1 (ko) 장시간 작용형 아드레노메둘린 유도체
JP2022543826A5 (https=)
JP2023500895A5 (https=)
CA2139947C (en) Calcium channel blocking polypeptide from agelenopsis aperta
JP2024525843A5 (https=)
JP2022502467A5 (https=)
CA2935026C (en) Lipidated prolactin-releasing peptides for lowering blood glucose
JP2012517425A5 (https=)
US20210115103A1 (en) Long-acting adrenomedullin derivative
US6075009A (en) Neuropeptide Y analogues, compositions and methods of lowering blood pressure
JP2006517520A5 (https=)
JP2004521952A5 (https=)
JP2006513229A (ja) 睡眠時無呼吸におけるソマトスタチンアナログの使用